• Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation
• Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Biosimilars Policy BARDA funding ASPR funding ARPA-H funding and implementation Industrial Supply and Financing IRA implementation Part D biosimilars utilization

Duration: September 4, 2015 to December 31, 2017

General Issues: Health Issues, Government Issues, Veterans, Taxation/Internal Revenue Code, Budget/Appropriations, Copyright/Patent/Trademark, Pharmacy, Medicare/Medicaid

Spending: about $3,787,500 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2015: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), White House Office, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Natl Security Council (NSC), Defense - Dept of (DOD), Executive Office of the President (EOP), Office of Science & Technology Policy (OSTP), Food & Drug Administration (FDA), Vice President of the U.S., Congressional Budget Office (CBO)